Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents

European Journal of Medicinal Chemistry

Volumn 45, Issue 10, 2010, Pages 4554-4561

  Delaine, Tamara ^a   Bernardes Génisson, Vania ^a   Quémard, Annaïk ^b   Constant, Patricia ^c   Meunier, Bernard ^d   Bernadou, Jean ^a  

^a CNRS   (France)

^b INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d Palumed   (France)

Author keywords

Antitubercular agent; Bi substrate inhibitor; Enoyl ACP reductase; Truncated isoniazid NAD adduct

Indexed keywords

1 (3 BROMOPHENYL) 1 HYDROXY 1,2 DIHYDROPYRROLO[3,4 C] PYRIDIN 3 ONE; 1 (3 DODECYLOXYPHENYL) 1 HYDROXY 1,2 DIHYDROPYRROLO[3,4 C]PYRIDIN 3 ONE; 1 (3 DODECYLOXYPHENYL) 1 HYDROXY 5 [2 (3 HYDROXYPROPYLOXY) 2 OXYETHYL] 3 OXO 2,3 DIHYDRO 1H PYRROLO[3,4 C]PYRIDIN 5 IUM BROMIDE; 1 (3 DODECYLOXYPHENYL) 5 [2 (ETHYLOXY) 2 OXOETHYL] 1 HYDROXY 3 OXO 1,2 DIHYDROPYRROLO[3,4 C]PYRIDINIUM BROMIDE; 1 (3 DODECYLPHENYL) 1 HYDROXY 1,2 DIHYDROPYRROLO[3,4 C]PYRIDIN 3 ONE; 1 (3 DODECYLPHENYL) 5 [2 (ETHYLOXY) 2 OXOETHYL] 1 HYDROXY 3 OXO 1,2 DIHYDROPYRROLO[3,4 C]PYRIDINIUM BROMIDE; 1 HYDROXY 1 (3 (4 NONYLPHENYL)PHENYL) 1,2 DIHYDROPYRROLO[3,2 C]PYRIDIN 3 ONE; 1 HYDROXY 1 (3 OCTYLPHENYL) 1,2 DIHYDROPYRROLO[3,2 C] PYRIDIN 3 ONE; 1 HYDROXY 1 (3 PROPEN 3 YL) 1,2 DIHYDROPYRROLO[3,2 C] PYRIDIN 3 ONE; 1,4 DIHYDROPYRIDINE DERIVATIVE; 3 HYDROXYPROPYL 3 AMINOCARBONYL [4 (3 DODECYCLOXYBENZOYL) 1,4 DIHYDROPYRIDIN 1 YL]ACETATE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ETHYL 3 AMINOCARBONYL [4 (3 DODECYLBENZOYL) 1,4 DIHYDROPYRIDIN 1 YL]ACETATE; ETHYL 3 AMINOCARBONYL [4 (3 DODECYLOXYBENZOYL) 1,4 DIHYDROPYRIDIN 1 YL]ACETATE; INHA PROTEIN; ISONIAZID; OXIDOREDUCTASE INHIBITOR; PYRIDINE DERIVATIVE; PYRIDINIUM DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; LIPOPHILICITY; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SUZUKI REACTION;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; HUMANS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; NAD; OXIDOREDUCTASES; TUBERCULOSIS;

EID: 77956184147     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.07.016     Document Type: Article

References (28)

1. C. Dye, S. Scheele, P. Dolin, V. Pathania, and M.C. Raviglione Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country J. Am. Med. Assoc. 282 1999 677 686
2. K. Bartmann, H. Iwainski, H.H. Kleeberg, P. Mison, H.H. Offe, H. Otten, D. Tettenborn, and L. Trnka K. Bartmann, Antituberculosis Drugs 1998 Springer Berlin
3. Y. Zhang, B. Heym, B. Allen, D. Young, and S. Cole The catalase-peroxydase gene and isoniazid resistance of Mycobacterium tuberculosis Nature 358 1992 591 593
4. K. Johnsson, and P.G. Schultz Mechanistic studies of the oxidation of isoniazid by the catalase peroxydase from Mycobacterium tuberculosis J. Am. Chem. Soc. 116 1994 7425 7426
5. K. Johnsson, D.S. King, and P.G. Schultz Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis J. Am. Chem. Soc. 117 1995 5009 5010
6. M. Nguyen, C. Claparols, J. Bernadou, and B. Meunier A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts ChemBioChem. 2 2001 877 883
7. III-pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 46 2002 2137 2144
8. R.I.J. Amos, B.S. Gourlay, C.H. Schiesser, J.A. Smith, and B.F. Yates A mechanistic study on the oxidation of hydrazides: application to the tuberculosis drug isoniazid Chem. Commun. 2008 1695 1697
9. A. Quémard, C. Lacave, and G. Lanéelle Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum Antimicrob. Agents Chemother. 35 1991 1035 1039
10. A. Quémard, J.S. Blanchard, W.R. Jacobs Jr., and J.C. Sacchettini Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis Science 267 1995 1638 1641
11. L. Kremer, and G.S. Besra Molecular action of antimycobacterial agents and mechanisms of drug resistance in Mycobacterium tuberculosis Recent Res. Devel. Antimicrob. Agents Chemother. 3 1999 453 470
12. T. Scior, I.M. Morales, S.J.G. Eisele, D. Domeyer, and S. Laufer Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis Arch. Pharm. (Weiheim, Ger) 335 2002 511 525
13. B. Saint-Joanis, H. Souchon, M. Wilming, K. Johnsson, P. Alzari, and S.T. Cole Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis Biochem. J. 338 1999 753 760
14. S. Yu, S. Girotto, C. Lee, and R.S. Magliozzo Reduced affinity for isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance J. Biol. Chem. 278 2003 14769 14775
15. B. Heym, P. Alzari, N. Honoré, and S. Cole Missense mutations in the catalase-peroxydase gene KatG, are associated with isoniazid resistance in Mycobacterium tuberculosis Mol. Microbiol. 15 1995 325 345
16. S.V. Ramaswamy, R. Reich, S.-J. Dou, L. Jasperse, X. Pan, A. Wenger, T. Quitugua, and E.A. Graviss Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis Antimicrob. Agents Chemother. 47 2003 1241 1250
17. L.A. Basso, R. Zheng, J.M. Musser, W.R. Jacobs Jr., and J.S. Blanchard Mechanism of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates J. Infect. Dis. 178 1998 769 775
18. L. Chen, G. Gao, L. Bonnac, D.J. Wilson, E.M. Bennett, H.N. Jayaram, and K.W. Pankiewicz Methylenebis (sulfonamide) linked nicotinamide adenine dinucleotide analogue as a inosine monophosphate dehydrogenase inhibitor Bioorg. Med. Chem. Lett. 17 2007 3152 3155
19. S. Brinster, G. Lamberet, B. Staels, P. Trieu-Cuot, A. Gruss, and C. Poyart Type II fatty acid synthesis is not a suitable antibiotic target for gram-positifs pathogens Nature 458 2009 83 86
20. D.T. Moir Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase Curr. Drug Targets Infect. Disord. 5 2005 297 305
21. S. Broussy, V. Bernardes-Génisson, H. Gornitzka, J. Bernadou, and B. Meunier Studies on the 4-benzoylpyridine-3-carboxamide entity as a fragment model of the isoniazid-NAD adduct Org. Biomol. Chem. 3 2005 666 669
22. S. Broussy, V. Bernardes-Génisson, A. Quémard, B. Meunier, and J. Bernadou The first chemical synthesis of the core structure of the benzoylhydrazine-NAD adduct, a competitive inhibitor of the Mycobacterium tuberculosis enoyl reductase J. Org. Chem. 70 2005 10502 10510
23. I-promoted Suzuki-Miyaura cross-couplings of n- alkylboronic acids Tetrahedron Lett. 42 2001 7213 7215
24. T. Delaine, V. Bernardes-Génisson, J.-L. Stigliani, H. Gornitzka, B. Meunier, and J. Bernadou Ring-chain tautomerism of simplified analogues of isoniazid-NAD(P) adducts: an experimental and theoretical study Eur. J. Org. Chem. 2007 1624 1630
25. J. Bernadou, V. Bernardes-Génisson, T. Delaine, A. Quémard, Novel anti-infectious derivatives, method for the production thereof, pharmaceutical compositions containing same and uses of said derivatives in treatment, Fr. Pat. 101 345 (2009).
26. A. Quémard, J.C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W.R. Jacobs Jr., and J.S. Blanchard Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis Biochemistry 34 1995 8235 8241
27. P. Goldman, and P.R. Vagelos The specificity of triglyceride synthesis from diglycerides in chicken adipose tissue J. Biol. Chem. 236 1961 2620 2623
28. S. Ducasse-Cabanot, M. Cohen-Gonsaud, H. Marrakchi, M. Nguyen, D. Zerbib, J. Bernadou, M. Daffé, G. Labesse, and A. Quémard In vitro inhibition of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein reductase MabA by isoniazid Antimicrob. Agents Chemother. 48 2004 242 249